Raise awareness this May for bladder cancer, its symptoms, and the importance of early detection to save lives.
ImmunityBio Inc. on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to ...
Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...
AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, ...
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...
Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.
In patients with very high risk, high grade T1 with CIS NMIBC, the possible value of adding immune checkpoint blockade to BCG has not been defined.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s ...
Cambridge-headquartered Bicycle Therapeutics is accelerating a timely battle against bladder cancer. The company, based at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results